Neil Jordan

Dr. Neil Jordan

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Circulation
Verified
Journal Article
Open access
PDF file
CKCiaran N. Kohli-Lynch
Ciaran N. Kohli-Lynch
JLJim Lewsey
Jim Lewsey
KBKathleen A. Boyd
Kathleen A. Boyd
DFDustin D. French
Dustin D. French
NJNeil Jordan
Neil Jordan
ABAndrew H. Briggs
Andrew H. Briggs
Background: Cholesterol guidelines typically prioritize primary prevention statin therapy based on 10-year risk of cardiovascular disease. The advent of generic pricing may justify expansion of statin eligibility. Moreover, 10-year risk may not be the optimal approach for statin prioritization. We estimated the cost-effectiveness of expanding preventive statin eligibility and evaluated novel approaches to prioritization from a Scottish health sector perspective. Methods: A computer simulation model predicted long-term health and cost outcomes in Scottish adults aged ≥40 years. Epidemiologic analysis was completed using the Scottish Heart Health Extended Cohort, Scottish Morbidity Records, and National Records of Scotland. A simulation cohort was constructed with data from the Scottish Health Survey 2011 and contemporary population estimates. Treatment and cost inputs were derived from published literature and health service cost data. The main outcome measure was the lifetime incremental cost-effectiveness ratio (ICER), evaluated as cost (GBP 2020) per quality-adjusted life year (QALY) gained. Three approaches to statin prioritization were analyzed: 10-year risk scoring using the ASSIGN score, age-stratified (Age-Strat) risk thresholds to increase treatment rates in younger individuals, and absolute risk reduction (ARR)-guided therapy to increase treatment rates in individuals with elevated cholesterol levels. For each approach, two policies were considered: one which treats the same number of individuals as an ASSIGN score ≥20% (ASSIGN 20, Age-Strat 20, ARR 20) and one which treats the same number as an ASSIGN score ≥10% (ASSIGN 10, Age-Strat 10, ARR 10). Results: Compared to ASSIGN 20, reducing the risk threshold for statin initiation to 10% expanded eligibility from 804,000 (32% of CVD-free adults aged ≥40 years) to 1,445,500 individuals (58%). This policy would be cost-effective (ICER: £12,300/QALY, 95% CI: £7,690/QALY-£26,500/QALY). Incremental to ASSIGN 20, ARR 20 produced around 8,800 QALYs and was cost-effective (£7,050/QALY, 95% CI: £4,560/QALY-£10,700/QALY). Incremental to ASSIGN 10, ARR 10 produced around 7,950 QALYs and was cost-effective (£11,700/QALY, 95% CI: £9,250/QALY-£16,900/QALY). Both age-stratified risk threshold strategies were dominated (i.e., more expensive and less effective than alternative treatment strategies). Conclusions: Generic pricing has rendered preventive statin therapy cost-effective for many adults. Absolute risk reduction-guided therapy is more effective than 10-year risk scoring and is cost-effective.

28 March 2014 in Administration and Policy in Mental Health and Mental Health Services Research
Verified
Journal Article
Closed access
PDF file
KCKa Ho Brian Chor
Ka Ho Brian Chor
GMGary M. McClelland
Gary M. McClelland
DWDana A. Weiner
Dana A. Weiner
NJNeil Jordan
Neil Jordan
JLJohn S. Lyons
John S. Lyons

21 September 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
LPLaura M. Perry
Laura M. Perry
VMVictoria Morken
Victoria Morken
JPJohn Devin Peipert
John Devin Peipert
BYBetina Yanez
Betina Yanez
SGSofia F. Garcia
Sofia F. Garcia
DCDavid Cella
David Cella
Background: Patient-reported outcomes—symptoms, treatment side effects, and health-related quality of life—are important to consider in chronic illness care. The increasing availability of health IT to collect patient-reported outcomes and integrate results within the electronic health record provides an unprecedented opportunity to support patients’ symptom monitoring, shared decision-making, and effective use of the health care system. Objective: The objectives of this study are to co-design a dashboard that displays patient-reported outcomes along with other clinical data (eg, laboratory tests, medications, and appointments) within an electronic health record and conduct a longitudinal demonstration trial to evaluate whether the dashboard is associated with improved shared decision-making and disease management outcomes. Methods: Co-design teams comprising study investigators, patients with advanced cancer or chronic kidney disease, their care partners, and their clinicians will collaborate to develop the dashboard. Investigators will work with clinic staff to implement the co-designed dashboard for clinical testing during a demonstration trial. The primary outcome of the demonstration trial is whether the quality of shared decision-making increases from baseline to the 3-month follow-up. Secondary outcomes include longitudinal changes in satisfaction with care, self-efficacy in managing treatments and symptoms, health-related quality of life, and use of costly and potentially avoidable health care services. Implementation outcomes (ie, fidelity, appropriateness, acceptability, feasibility, reach, adoption, and sustainability) during the co-design process and demonstration trial will also be collected and summarized. Results: The dashboard co-design process was completed in May 2020, and data collection for the demonstration trial is anticipated to be completed by the end of July 2022. The results will be disseminated in at least one manuscript per study objective. Conclusions: This protocol combines stakeholder engagement, health care coproduction frameworks, and health IT to develop a clinically feasible model of person-centered care delivery. The results will inform our current understanding of how best to integrate patient-reported outcome measures into clinical workflows to improve outcomes and reduce the burden of chronic disease on patients and health care systems. International Registered Report Identifier (IRRID): DERR1-10.2196/38461

1 March 2009 in Chest
Verified
Journal Article
Closed access
PDF file
NJNeil Jordan
Neil Jordan
TLTodd A. Lee
Todd A. Lee
MVMarcia Valenstein
Marcia Valenstein
PPPaul A. Pirraglia
Paul A. Pirraglia
KWKevin B. Weiss
Kevin B. Weiss

9 August 2007 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
NJNeil Jordan
Neil Jordan
TLTodd A. Lee
Todd A. Lee
MVMarcia Valenstein
Marcia Valenstein
KWKevin B. Weiss
Kevin B. Weiss